WoodenScale AI

Tag: startup funding india

  • Plum Insurance Raises ₹193 Cr for Broader Care

    Plum Insurance Raises ₹193 Cr for Broader Care

    Plum Insurance sells health insurance and employee health benefits to businesses in India. The insurtech startup has raised ₹193 Cr ($20.6 Mn) in a Series B round led by Peak XV Ventures, as employers keep looking for simpler ways to manage coverage, claims, and day-to-day healthcare support for teams. Founded in 2019 by Abhishek Poddar and Saurabh Arora, Plum is now trying to turn that insurance relationship into something much wider than a policy purchase. It wants to own more of the employee healthcare experience, not just the paperwork around it.

    What is Plum Insurance and how does it work?

    At the most basic level, Plum Insurance gives employers a digital system to buy and run group health cover without the usual broker-heavy mess. Companies can choose a plan and enroll employees. They can add or remove members, manage dependents, and track usage from an admin dashboard instead of juggling spreadsheets and back-and-forth emails. Employees get their own dashboard to view benefits, check policy details, and start claims.

    Plum also goes beyond policy administration. Its product stack now stretches into claims support and preventive care. It also includes telehealth and health checkups. On the employee side, the platform offers digital access to teleconsultations and wellness perks. On the diagnostics side, Plum’s newer health checkup product uses biomarker-based screening and AI-generated explanations. It also includes doctor consultations and follow-up monitoring through telehealth.

    The practical change is pretty clear. Before this kind of software, HR teams often dealt with insurers and brokers. They also had to handle paper forms and slow claim updates. Plum replaces a lot of that with self-serve enrollment and real-time claim status. It also adds benefits usage tracking, plus WhatsApp-based claim filing and policy access. That’s not minor.

    Who founded Plum Insurance and why are they credible?

    The founding story

    Plum was founded in 2019 by Abhishek Poddar and Saurabh Arora as a B2B insurtech platform serving SMEs and startups. The original idea was pretty direct: make employee insurance easier to buy and easier to understand. It also aimed to make the process less opaque for smaller companies that were often ignored or overcharged by traditional channels. Earlier reporting on the company noted that the old buying process could take around 8 weeks, and pricing distortions from intermediaries were a real issue for smaller employers.

    Why Poddar and Arora fit this market

    Poddar came into Plum with product and startup experience rather than old-school insurance credentials. Before Plum, he worked on an earlier version of Google Pay as a product manager, built HyperTrack, and earlier started RentZeal. He’s also a Stanford Business School alumnus. That matters because Plum is a software-first insurance business, not just a reseller with a cleaner website.

    Arora’s background tilts even harder toward product building. He co-founded Airwoot, which was later acquired by Freshworks, then became a product head there. He’d also worked on ventures like Filter.ly and Startereum. So when Plum talks about AI-driven claims operations and deeper HR or payroll integrations, it doesn’t sound bolted on after the fact. It fits the founders’ histories.

    Traction, fundraising, and where Plum sits against rivals

    Plum now serves more than 6,000 organisations, including Zomato, Swiggy, Atlassian, and CRED. This Series B comes after its first full year of EBITDA and cash flow profitability. That’s a stronger signal than raw growth alone. In a market where a lot of insurtech companies were once judged mostly on GMV and branding, profitability gives this round a different tone.

    The round itself totals ₹193 Cr ($20.6 Mn). Peak XV Ventures led it, with Tanglin Venture Partners and GMO Venture Partners also participating. Plum will use the money for talent acquisition and technology investment. It also plans to spend on enterprise-grade security, AI-driven claims operations, tighter HR and payroll integrations, and a broader employee healthcare product. It’s also planning to push beyond claims into preventive care and primary care. Mental wellness and telehealth are part of that plan too. As CEO Abhishek Poddar put it, “This round gives us the capital to move faster on what we know works, while expanding the platform across healthcare and employee benefits.”

    This isn’t the first sign of that direction. Back in July 2025, Plum was planning a ₹200 Cr push into health services through a separate offering called Plum Health. That offering was built around diagnostics, teleconsultations, and AI-powered health tracking. So this Series B looks less like a sudden pivot and more like funding behind a roadmap already in motion.

    Where Plum Insurance stands against competitors

    Plum’s closest direct rivals are platforms like Onsurity and Nova Benefits, both of which also pitch employers on digital employee healthcare and insurance administration. Onsurity has leaned into a monthly subscription model for SMEs and raised $24 million in a Series B led by IFC in 2025. Nova Benefits built its early pitch around a unified employee benefits app and plan selection help. Faster claims resolution was part of that too.

    But Plum’s positioning is slightly broader now. Its edge isn’t just policy placement. It’s trying to sit across enrollment and claims. Claims visibility, telehealth, preventive screening, and wellness access are part of the same system. Against legacy alternatives — brokers, insurer portals, Excel sheets, email threads — that bundled operating layer is the actual product. Investors are probably betting that once Plum becomes the default health benefits workflow for HR teams, it gets a lot harder to replace.

    Why does Plum Insurance matter after this Series B?

    Here’s why this round matters: Plum isn’t using the money just to sell more insurance. It’s using it to build a thicker product.

    That changes the revenue logic. A company that only helps place a policy is easier to compare on price. A company that also handles claims operations and employee support is much stickier. Telehealth, diagnostics, and data flowing into HR systems add to that. For customers, that could mean less admin work and better visibility. For Plum, it could mean more recurring relevance inside the employer workflow.

    But there’s real execution risk too. Expanding from insurance into primary care, mental wellness, and preventive health sounds smart on paper. It also means dealing with very different service expectations. Claims software is one thing. Ongoing care delivery is another. This round gives Plum room to try both.

    How big is the market Plum Insurance is chasing?

    The market tailwind is big enough to explain why investors still care about health insurtech. Grand View Research projects India’s health insurance market will reach $46.37 billion by 2030, growing at a 20.9% CAGR from 2025 to 2030. Corporate policies already made up 71.21% of the market’s revenue share in 2024. That tells you employer-sponsored coverage is not some niche corner of the sector.

    The wider insurtech story is still alive, just less reckless than before. BCG says India has more than 150 active insurtech players with cumulative valuations above $15.8 billion, and health insurtechs accounted for more than 70% of sector funding in 2024. IRDAI-linked reporting has described group health insurance as one of the strongest structural drivers inside non-life insurance, while Aon expects employee medical plan costs in India to rise 11.5% in 2026. That cost pressure is exactly why employers are looking harder at prevention, telehealth, and better claims control.

    Final take on Plum Insurance

    Plum Insurance has moved past the stage where “digital broker” is enough of a story. This Series B is a bet that employers want one platform for insurance administration and a lot more care around it. The next thing to watch is simple: whether Plum can turn preventive care, telehealth, and AI-led claims into a durable product advantage instead of a longer feature list.

    Read how ELMED Life Sciences Raises $2.7M to Scale Probiotics and why microbiome manufacturing is becoming critical across healthcare and agriculture.

    FAQ

    What was Plum Insurance’s Series B funding round?

    Plum Insurance raised ₹193 Cr, or about $20.6 Mn, in its Series B round. Peak XV Ventures led the investment, with Tanglin Venture Partners and GMO Venture Partners participating, and the company said the money will go into hiring, product, security, and AI-led claims operations.

    How does Plum Insurance work for employers?  

    Plum gives companies a digital platform to manage group health insurance and employee healthcare benefits in one place. Employers can enroll staff and update dependents. They can track claims and monitor benefits usage, while employees get dashboards, telehealth access, and digital claims support — including WhatsApp-based flows.

    Who founded Plum Insurance?  

    Plum Insurance was founded in 2019 by Abhishek Poddar and Saurabh Arora. Poddar previously worked on an earlier version of Google Pay and built startups like HyperTrack, while Arora earlier co-founded Airwoot before joining Freshworks after its acquisition.

    Is Plum Insurance a healthtech company or an insurtech company?  

    It’s both, but it started squarely as an insurtech company focused on employer-sponsored health coverage. What’s changing now is that Plum is expanding into telehealth, preventive care, diagnostics, mental wellness, and AI-supported health tracking, which pushes it deeper into healthtech territory as well.

  • ELMED Life Sciences Raises $2.7M to Scale Probiotics

    ELMED Life Sciences Raises $2.7M to Scale Probiotics

    ELMED Life Sciences makes probiotic products for healthcare and agri-biotech companies, and it has now raised $2.7 million in Series A funding from NABVENTURES-managed AgriSURE Fund. It’s chasing a simple but messy problem: reliable microbiome products are still hard to manufacture across human health, animal health, aquaculture, and agriculture. Founded in 2018 by VIT alumni Pruthivin Reddy Madduri and Nikhil Konkathi, the Hyderabad company plans to use the fresh capital to expand production capacity in the city. It also wants to deepen microbiome-focused R&D and push harder into Tier II and Tier III India as well as overseas markets.

    That’s a meaningful step for a company in a less flashy part of the business. ELMED isn’t selling a wellness story first. It’s building the formulations and manufacturing backbone that let other brands and healthcare businesses sell probiotic products at all.

    What does ELMED Life Sciences actually make?

    ELMED Life Sciences is a probiotic manufacturer and formulation partner. It works across human health, animal health, aquaculture, and agriculture. Its business spans contract manufacturing and research and development services for outside companies. Its catalog covers multiple dosage forms and use cases rather than one narrow gut-health SKU.

    The human-health side is especially broad. ELMED sells probiotics in vials, capsules, sachets, syrups, and drops, with product examples built around strains such as Bacillus clausii, Bacillus coagulans, Bacillus subtilis, and Saccharomyces boulardii. Some listings are very specific. Triogermila is a 6 billion CFU oral suspension. Endogermila is a Bacillus clausii vial product, and Bacimed is a syrup based on Bacillus subtilis CU1.

    That format flexibility matters for customers. A pharma or healthcare brand that wants a room-temperature probiotic in orange-flavored vials has a different manufacturing need from an aquaculture buyer that wants a bacillus-and-pediococcus blend for Vibrio control. An agriculture buyer may be looking for microbial products aimed at soil and water hygiene. ELMED already shows all of those in-market formats, including aquaculture products like VIBRICON and agriculture products like ELTOX.

    Taken together, the product catalog points to a practical workflow: strain-led formulation work, dosage-form selection, then scaled manufacturing under one roof. That’s the pitch. Instead of a brand stitching together R&D and production from different vendors, ELMED is trying to collapse that into a single specialist partner. It serves 150+ clients, supports 250+ brands, exports to 18+ countries, and holds 15+ global certifications.

    Who founded ELMED Life Sciences and what’s its edge?

    The founding story

    ELMED was founded in 2018 in Hyderabad by Pruthivin Reddy Madduri and Nikhil Konkathi. The company formally dates to December 13, 2018, and both founders have been on the board since launch. The startup began with a focused bet on probiotics rather than a broad nutraceutical sprawl. That matters because probiotic manufacturing is unforgiving on strain stability, quality control, and dosage-form execution.

    Both founders are VIT alumni, and the company has kept its manufacturing base in Hyderabad — a city that already has the supplier base, pharma talent, and export muscle needed for a business like this.

    Founder market fit

    Pruthivin Reddy Madduri brings a slightly unusual profile for this category. His background is in computer science at VIT, followed by graduate study at California State University, Fullerton, and he has described prior exposure to the U.S. healthcare sector before starting ELMED. He isn’t a bench scientist. But it helps explain why ELMED leans into formulation, process, and product architecture instead of just branding.

    Public founder detail on Konkathi is thinner, but he has been there since incorporation and is listed as director across company profiles and industry listings. One older profile on the founding team says both founders worked in healthcare companies after their master’s studies before starting up together in Hyderabad.

    Traction and early signals

    This is not a pre-product story. ELMED is already operating with a commercial catalog, a manufacturing plant in Cherlapalli, and a customer base large enough to matter. It has 150+ clients and 250+ brands across markets, while the source article names Xanum, Hetero Healthcare, Wallace Pharmaceuticals, and Donovan among its top customers. ELMED also exports to more than 18 countries and wants to go deeper into Europe, Asia, and Latin America.

    Its facility is built to produce oral suspensions, emulsions, drops, capsules, sachets, and syrups across therapeutic areas for humans, aquatic life, animals, and plants. That breadth is a real signal. Lots of startups talk about microbiome science. Fewer have translated that into multiple commercial form factors.

    Fundraising details and competition

    The company’s Series A totals $2.7 million, or ₹25.4 crore, from NABVENTURES-managed AgriSURE Fund. ELMED will use the money for more production capacity in Hyderabad. It also plans stronger R&D in microbiome-based solutions and wider distribution across smaller Indian cities while expanding internationally.

    Competition is crowded but fragmented. In India, probiotic manufacturing and contract work already includes established names such as Unique Biotech, Sanzyme Biologics, and other specialist manufacturers that compete on fermentation know-how, certifications, and export readiness. The legacy alternative is even tougher: big pharma brands that outsource probiotic production to experienced contract manufacturers with long regulatory track records. ELMED’s differentiator is its cross-sector footprint — one company serving human health, aquaculture, animal health, and agriculture — plus a dosage-form mix that goes beyond capsules into suspensions, emulsions, drops, and farm-use microbial products.

    Why does ELMED Life Sciences funding matter?

    This round matters because it shifts ELMED from “credible specialist” toward “scaled platform” , if execution holds up. Production capacity in probiotics isn’t a cosmetic upgrade. It decides how many brands a manufacturer can serve, how consistently it can deliver sensitive strains, and whether it can win larger accounts that don’t tolerate supply shocks.

    The R&D piece is just as important. Microbiome products get more valuable when a company can tailor strains, delivery formats, and applications to different end markets. Human gut-health products need one kind of evidence and formulation discipline. Aquaculture and agriculture need another. ELMED is trying to own that complexity instead of staying a plain-vanilla bulk producer.

    There’s also the investor angle. NABVENTURES backing this round through AgriSURE suggests the thesis isn’t only about consumer wellness. It’s also about applied microbiome science in rural and agricultural settings, where probiotics can move from supplements into productivity and preventive-health tools.

    How big is the probiotics and microbiome market?

    The market tailwind is real, even if the exact number depends on what you count. IBEF, citing PharmaTrac, said India’s probiotics market reached ₹2,070 crore in 2025 after roughly doubling in five years and growing 22% on a moving annual total basis in May 2025. IMARC’s broader estimate put India’s probiotics market at $2.2 billion in 2024, with projected CAGR of 17.8% from 2025 to 2033.

    That gap in estimates isn’t unusual. Some reports focus tightly on probiotic products sold in certain channels. Others include wider food, supplement, and wellness categories. Either way, this isn’t a fringe category anymore.

    The global picture is larger still. IMARC estimated the worldwide probiotics market at $71.9 billion in 2025, with a path to $124 billion by 2034. That scale helps explain why ELMED wants deeper exposure to Europe, Asia, and Latin America rather than staying domestic.

    Investor behavior backs that up. On May 6, 2025, Mumbai-based gut-health startup The Good Bug raised ₹100 crore to scale microbiome R&D and expand distribution, showing that capital is still flowing into this segment when companies can tie science to commercial demand. Closer to ELMED’s own category, the broader Indian probiotics industry is also benefiting from demand for natural, preventive, and non-antibiotic solutions across both healthcare and agriculture.

    Final take on ELMED Life Sciences

    ELMED Life Sciences isn’t the loudest startup in microbiome health. That may actually help. It’s a building where a lot of the hard value sits — formulation, manufacturing, and cross-category probiotic infrastructure.

    Watch whether ELMED can convert this round into faster capacity build-out, deeper R&D, and real distribution wins outside metros without losing quality discipline.

    Read how Deccan AI Raises $25M for Post-Training Stack and why enterprises are investing in tools that make AI systems reliable in production.

    FAQ

    What funding did ELMED Life Sciences raise?

    ELMED Life Sciences raised $2.7 million in a Series A round. The investor was NABVENTURES-managed AgriSURE Fund, and the company is putting that money into manufacturing expansion in Hyderabad, microbiome R&D, and market expansion in India and overseas.

    What does ELMED Life Sciences sell?

    ELMED sells and manufactures probiotic products across human health, animal health, aquaculture, and agriculture. Its catalog includes vials, capsules, sachets, syrups, drops, and farm-use microbial products, with examples built around strains like Bacillus clausii and Saccharomyces boulardii.

    Who founded ELMED Life Sciences? 

    ELMED was founded in 2018 by Pruthivin Reddy Madduri and Nikhil Konkathi, both VIT alumni. Madduri’s profile includes computer science training, graduate study in California, and prior exposure to the U.S. healthcare sector before launching the business in Hyderabad.

    Is ELMED Life Sciences a gut-health brand or a biotech manufacturer?

    It’s much closer to a biotech manufacturer and contract development partner than a consumer-first gut-health brand. Unlike companies that mainly sell probiotics directly to shoppers, ELMED works behind the scenes on formulation, R&D, and production for healthcare and agri-biotech customers.

  • Deccan AI Raises $25M for Post-Training Stack

    Deccan AI Raises $25M for Post-Training Stack

    Deccan AI builds post-training, evaluation, and deployment tools for enterprise AI models. The AI infrastructure startup has now raised $25 million in a round led by A91 Partners, with Susquehanna and existing backer Prosus Ventures also participating. Lots of companies can access strong models now, but far fewer can safely train, test, and run them inside real business workflows without things breaking. Founded in 2023 by Rukesh Reddy, the company is betting that this messy middle layer — between a foundation model and a usable enterprise system — is where a lot of the value will sit.

    What is Deccan AI and how does it work?

    Deccan AI is trying to sell enterprises a full post-training stack, not a single AI feature. Its portfolio now includes STARK RL envs, Helix evals, and EnterpriseOS agents. In plain English, that means one layer for training agents in realistic conditions, one for generating and managing evaluation data, and one for deploying those systems into operating workflows.

    The most concrete piece is STARK RL envs — the STARK RL gym. It simulates enterprise servers, tools, permissions, latency, rate limits, and irreversible actions so an AI agent can learn inside a controlled environment before touching live systems. The setup includes tasks, verifiers, golden trajectories, a sandbox container, plug-and-play LLM endpoints, and a Python SDK for training and evaluation. That’s a lot more useful than a toy benchmark. Enterprise failures usually come from workflow edge cases, not just bad prompt wording.

    Helix evals sits closer to the data problem. It’s a data-generation tool for building, managing, and scaling high-quality training data, and that lines up with Deccan’s broader platform emphasis on expert-built datasets, model evaluation, domain-specific tuning for RAG, Text2SQL, coding, STEM, multimodal work, and agentic systems. The pitch isn’t “we’ll give you generic labels.” It’s “we’ll help you create the sort of evaluation and post-training data that enterprise models usually don’t have enough of.”

    Then there’s EnterpriseOS agents. Deccan’s workflow for customers starts with understanding the business process and data sources. Then it customizes and trains a model on company data, and deploys and monitors it with a UI builder, sandbox testing, and real-time orchestration. Before that, a lot of this work lives in internal prompt hacks, manual QA, and scattered scripts. Afterward, the company is promising something closer to a managed production layer for enterprise AI. Ambitious? Yes. But the product logic is coherent.

    Who founded Deccan AI and why now?

    The founding story

    Deccan AI was founded in 2023 by Rukesh Reddy. The company helps enterprises train, evaluate, and deploy AI across agentic workflows, coding, functional streams, and robotics — which explains why the new round is earmarked not just for post-training data and R&D, but also for enterprise-grade infrastructure and robotics-relevant data. It operates from the Bay Area, Hyderabad, and Bangalore. That fits the model: close to enterprise buyers in the US, deep talent delivery from India.

    Why Rukesh Reddy fits this market

    Reddy doesn’t come out of an academic AI lab. He comes from operating roles in finance and consulting — 15+ years across Citi, Monitor, and JPMorgan, with IIT Bombay and IIM Ahmedabad on the résumé. He also spent time at 360 ONE Wealth, where he led growth for the digital wealth business. That background matters because Deccan isn’t selling research demos. It’s selling reliability and process design. Enterprise trust, too.

    Earlier operating experience

    Before launching this company, Reddy held roles including SVP for strategy and business development in Citi’s global retail bank, US head of CX and digital transformation at Citi, and general manager for Citigold. He also founded Soul AI in 2023, another venture centered on RLHF and enterprise generative AI services. So while he isn’t a household-name model researcher, he does have a track record in complex operating environments where workflows, compliance, and customer experience are the whole game.

    Early traction and signals

    This isn’t pre-product vapor. Deccan AI already counts Google and Snowflake among its customers. The company has also built a talent pool of more than 500,000 specialists across 25+ domains for high-quality AI data and evaluation work — an important asset if your business depends on difficult post-training workflows rather than commodity annotation. It has also put enterprise certifications like SOC 2, ISO 27001, GDPR, and HIPAA front and center, which tells you exactly who it wants to sell to.

    Funding details

    The new round brings in $25 million, led by A91 Partners, with Susquehanna and Prosus Ventures participating. Deccan will use the money to scale post-training data, expand R&D, build enterprise-grade infrastructure, and deepen its datasets for enterprise use cases and robotics. That comes after Prosus had already backed the company in an earlier financing announced in May 2025.

    Competition and positioning

    This category is getting crowded fast. On the data and post-training side, enterprises can look at firms like Scale AI and Snorkel AI. On the evaluation side, buyers increasingly compare tools from Patronus AI, Arize, and Statsig, all of which focus on measuring model quality, production behavior, or guardrails in one form or another.

    Deccan is trying to bundle the ugly parts together. Instead of only selling eval dashboards or only selling data services, it offers a chain from domain data creation to simulated RL training to live workflow deployment. Legacy alternatives are still messy — internal AI teams, outsourced contractor networks, systems integrators, and spreadsheet-heavy QA loops. Deccan’s bet is that enterprises would rather buy one stack that mirrors real operational failure modes than stitch together 4 vendors and hope the seams hold.

    Why does Deccan AI’s $25M round matter?

    This isn’t growth capital for a simple SaaS seat-expansion story. The money is going into post-training data, R&D, and hardened infrastructure — the expensive stuff that determines whether an AI product survives contact with a real company. If Deccan executes well, it could move from being a useful vendor in model training and evals to something closer to a core enterprise AI plumbing layer.

    For customers, that matters more than another flashy model demo. A lot of enterprise AI projects still fail in the handoff from benchmark to production. Deccan’s product set is built around that exact failure point. It trains agents on realistic workflows. It generates the right eval data, then deploys into live processes with monitoring and iteration. That’s a much less glamorous pitch than “we built a new model,” but it’s where many buyers are finally willing to spend.

    For investors, the logic is pretty clear. Deccan already has known enterprise names on its customer list, a cross-border operating setup, and a product roadmap that maps neatly to where enterprise AI pain is heading. The hard part now isn’t whether there’s demand. It’s whether the company can scale quality without turning into just another labor-heavy services business wearing an infrastructure label.

    Why are investors betting on AI post-training now?

    The market tailwind is real. Gartner forecast worldwide generative AI spending at $644 billion in 2025, up 76.4% from 2024, and put software GenAI spending at $299 billion in 2025 with a path to $895 billion by 2028. That doesn’t mean every startup wins. It does mean the budget line is no longer theoretical.

    Adoption is also getting broad enough that quality problems can’t be brushed aside as “pilot noise”. McKinsey’s 2025 global survey found 88% of respondents said their organizations were using AI in at least one business function, up from 78% a year earlier. But only about one-third said their companies had begun scaling AI programs, and just 23% reported scaling an agentic AI system somewhere in the business. That gap — lots of usage, much less dependable scale — is exactly where post-training, evals, and production workflow tooling become valuable.

    There’s another shift underneath all this. Enterprises are getting less excited by raw model access and more obsessed with accuracy, governance, and workflow fit. Gartner even noted that many CIOs are growing dissatisfied with early proof-of-concept results and are leaning toward more predictable commercial solutions. So startups that can improve reliability after the model is chosen have a much clearer story than they did 18 months ago.

    What should customers watch from Deccan AI next?

    The thing to watch isn’t whether Deccan AI can add more product names to the site. It’s whether it can turn this three-part stack into a repeatable enterprise system with visible depth in a few verticals — especially robotics and other high-risk workflows where failure costs are real.

    If that happens, this round will look smart.

    If it doesn’t, Deccan AI risks getting squeezed between pure-play eval startups on one side and giant data infrastructure vendors on the other. That’s why the next 12 months matter so much. The company has money, customers, and a believable thesis. Now it has to prove the stack holds together at scale.

    Read how Ultrahuman Secures ₹400 Crore in Series C Funding and why its smart ring-led health platform is taking on global wearable leaders.

    FAQ

    What is the latest Deccan AI funding round?

    Deccan AI has raised $25 million in a round led by A91 Partners. Susquehanna and existing investor Prosus Ventures also joined, and the capital will be used for post-training data, R&D, enterprise infrastructure, and robotics-focused datasets.

    How does Deccan AI work for enterprise customers?

    Deccan AI combines training environments, evaluation tooling, and deployment software into one stack. A customer can simulate workflows in STARK RL envs, build higher-quality data and tests through Helix evals, and then push AI agents into operational systems through EnterpriseOS-style deployment tools.

    Who founded Deccan AI?

    Rukesh Reddy founded the company in 2023. His background spans Citi, Monitor, JPMorgan, and 360 ONE Wealth, and he studied at IIT Bombay and IIM Ahmedabad — which helps explain why Deccan’s pitch feels more enterprise-operations-heavy than research-lab-heavy.

    Is Deccan AI an AI infrastructure startup or an AI services company? 

    It sits in an awkward but interesting middle ground. Deccan AI looks like an AI infrastructure startup because it sells productized tooling for post-training, evaluation, and deployment, but its human-expert data engine is also a big part of the value. That hybrid model could be a strength if customers want outcomes, not just software.

  • DrinkPrime funding: Bengaluru water purifier startup raises ₹20 Cr at $36.8 Mn valuation

    DrinkPrime funding: Bengaluru water purifier startup raises ₹20 Cr at $36.8 Mn valuation

    Clean drinking water is a basic need, but buying and maintaining a purifier in India is still weirdly expensive and messy. That’s the gap DrinkPrime is chasing, and its latest DrinkPrime funding update shows investors still like the bet: the Bengaluru startup has raised ₹20 crore, plus an undisclosed debt component, to expand its smart subscription-based water purifier business.

    DrinkPrime rents out IoT-enabled RO+UV purifiers on monthly plans starting at ₹349, with installation and maintenance bundled in. The new money comes as the company pushes into more cities, more products, and a bigger field service network.

    What is DrinkPrime funding and why are investors backing it now?

    DrinkPrime has closed an extended Series A round of ₹20 crore, roughly $2.2 million, with participation from new investors Mirabilis Investment Trust and Artha Continuum Fund. Regulatory filings show the board approved the issue of 21,718 Series A3 compulsorily convertible preference shares at a face value of ₹10 and a premium of ₹9,195 per share through a preferential allotment.

    The round also included undisclosed debt. That matters because this isn’t a pure software startup. It runs a hardware-plus-service model, so debt can be useful for financing inventory, installations, and field operations without piling all of that onto equity.

    The fresh round has pushed DrinkPrime’s valuation to ₹340 crore, or about $36.8 million. That’s up roughly 31% from ₹260 crore in its previous round. In 2024, the startup had already raised $3 million in a round led by SIDBI Venture Capital alongside existing investors.

    Here’s the short version for anyone Googling the company: DrinkPrime is a Bengaluru-based water purifier subscription startup founded in 2016. It offers IoT-enabled RO+UV purifiers on monthly rental plans, including installation and maintenance. The company has now raised ₹20 crore in an extended Series A round, taking its valuation to about $36.8 million.

    Investors are backing a pretty simple thesis. Safe water is non-negotiable. Upfront purifier costs are annoying. After-sales service from legacy brands is often inconsistent. A recurring revenue model with predictive maintenance, data analytics, and lower customer friction is easier to scale than old-school appliance selling, at least in theory.

    That theory is starting to show up in the numbers. DrinkPrime says it has served more than 2 lakh households. Revenue in FY25 rose 54% to ₹72.1 crore from ₹46.8 crore a year earlier, while net loss narrowed 18.4% to ₹11.5 crore from ₹14.1 crore.

    What is DrinkPrime and how did the founders build it?

    DrinkPrime was founded in 2016 by Manas Ranjan Hota and Vijender Reddy Muthyala. The company started with a clear consumer pain point: in many Indian cities, water quality varies sharply by neighborhood, but purifier buying is still treated like a one-time appliance purchase. That’s clunky. Families pay a big upfront amount, then deal with service calls, filter changes, and maintenance headaches later.

    The founding story

    The founders built DrinkPrime around a different idea. Don’t sell a purifier like a refrigerator. Offer purified water as a managed household service.

    That shift sounds small, but it changes the whole customer relationship. Instead of asking a family to spend thousands upfront, DrinkPrime installs a connected purifier and charges a monthly subscription. The company then owns the service burden. If something breaks, it’s on DrinkPrime. If filters need replacing, same story.

    That’s why the startup’s IoT stack matters. The purifier isn’t just a box under the sink or on the kitchen wall. It’s part of a connected appliance network that can feed usage data, service alerts, and maintenance signals back to the company. In plain English, that means fewer surprise breakdowns and a better shot at predictive maintenance.

    Founder market fit

    Detailed public biographies for Hota and Muthyala are limited in the funding announcement itself, and the company hasn’t widely disclosed long CV-style founder histories in the way bigger late-stage startups often do. So it’s worth being careful here.

    What is clear is their market fit through execution. They’ve spent nearly a decade building in a category that mixes consumer hardware, subscription commerce, field operations, and data-led servicing. That’s not easy. Lots of startups can build a direct-to-consumer brand. Far fewer can manage purifier installations, recurring billing, customer support, and on-ground maintenance across multiple cities.

    Frankly, that operating complexity is part of the moat. A lot of founders can pitch a recurring revenue business. Fewer can actually run one in Indian home services.

    Past ventures and track record

    No major previous exits or well-documented earlier startups by the founders were publicly disclosed in the material around this round. That doesn’t mean there weren’t earlier roles or ventures. It just means they weren’t clearly stated, and guessing would be sloppy.

    Their visible track record is DrinkPrime itself. Since launch, the company has built a live product, expanded across major urban areas, and reached over 2 lakh households. It also developed a product lineup that now includes DrinkPrime Copper, DrinkPrime Alkaline, DrinkPrime UTS, DrinkPrime RO+, and DrinkPrime Under the Sink.

    Traction, team, and fundraising details

    DrinkPrime is very much live and commercial, not a pilot-stage business. It says it has already served more than 200,000 households and now wants to reach 1 million households over the next three years while scaling to 20 cities.

    The company hasn’t publicly pinned down current headcount in this announcement, though its operating model clearly requires teams across product, customer support, field service, supply chain, and city operations. That matters because this is closer to an operationally heavy consumer tech company than a lightweight enterprise software business.

    As for the money, the plan is specific. DrinkPrime says the fresh capital will go toward strengthening its IoT and data capabilities, expanding field service infrastructure, supporting R&D, and preparing new product launches. It also wants to enter high-growth tier II cities, build offline retail distribution, and add AI-driven processes to improve customer experience.

    There’s a useful adjacent read here on how recurring-revenue consumer startups are being valued in India. 

    How does DrinkPrime funding shape its product and business model?

    DrinkPrime’s product is easy to understand. Customers subscribe to a water purifier instead of buying one outright. Plans start at ₹349 per month. Installation and maintenance are included. The purifiers are tailored to local water conditions, which matters because water quality in India isn’t one-size-fits-all.

    The company’s devices are built around RO+UV purification, with connected hardware that feeds into a data layer. That data layer helps with service scheduling, purifier health monitoring, and customer support workflows. In startup language, this is a consumer appliance business with workflow automation and analytics automation built into the backend.

    That doesn’t make it an enterprise software company, obviously. But some of the same logic applies. Better data means better board reporting, tighter financial reporting, and smarter operational decisions. If DrinkPrime can predict service needs before customers complain, that improves retention and unit economics.

    The company also says it plans to integrate AI-driven processes. For now, that likely means internal optimization rather than flashy AI agents talking to consumers. Think service routing, maintenance prioritization, support triage, and maybe demand forecasting. Not agentic AI in the buzzy sense. More practical automation. Honestly, that’s probably the right call.

    DrinkPrime’s latest DrinkPrime funding round is really a bet that connected appliances plus subscription billing plus strong service can beat the old hardware-sales model in a necessity category.

    How does DrinkPrime compare with Kent, Aquaguard, Livpure, and other rivals?

    This is the mandatory question, because funding news without market positioning is just noise.

    DrinkPrime sits in a crowded water purifier market with several layers of competition. The direct competitors are brands offering home water purification, especially those with subscription or service-heavy models. Livpure is the closest comparison in spirit because it has also pushed smart and subscription-led offerings. Then there are giant incumbents like Kent RO, Eureka Forbes’ Aquaguard, Pureit, and AO Smith, all of which still have much stronger brand recognition in purifier ownership.

    Indirect competition is broader. It includes local purifier rental shops, neighborhood service providers, and even households that simply keep using bottled water, can deliveries, or basic non-electric filters. The legacy alternative, though, is still the classic buy-and-maintain model: pay upfront, then hope after-sales service is decent.

    DrinkPrime’s differentiation is pretty clear. It lowers upfront cost, wraps maintenance into one monthly fee, and uses IoT-enabled monitoring to improve service reliability. That’s a cleaner pitch for renters, younger families, and urban consumers who don’t want another appliance headache.

    But there’s a catch. The company is taking on operational risk that incumbents can partly offload to dealer networks and annual maintenance contracts. Field service quality will make or break this model. If service slips, the subscription pitch falls apart fast.

    Still, the numbers suggest momentum. A 54% revenue jump in FY25 is real. So is the 31% valuation increase. That’s why investors are still interested, even in a market where consumer brands don’t get easy money anymore.

    For readers tracking the broader home-tech and D2C startup funding cycle, this is another useful comparison point.

    Why does DrinkPrime funding matter for the Indian water purifier market?

    Because it says something bigger about where the category is headed.

    India’s water purifier market is already worth several thousand crore rupees by most industry estimates, and many forecasts expect double-digit growth over the next few years as urbanization, health awareness, and water contamination concerns keep rising. The subscription slice is still smaller than outright ownership, but it’s growing because consumers increasingly prefer access over ownership in categories with ongoing maintenance.

    That trend isn’t unique to water. You see versions of it in appliances, mobility, software, and even finance tools. People don’t always want to own the thing. They want the outcome. In this case, the outcome is safe drinking water without surprise repair bills.

    DrinkPrime’s COO Sanjay Sunku put the ambition plainly: “This capital will help us accelerate our growth as we scale DrinkPrime to 20 cities and work towards serving 1 Mn households over the next three years.”

    The company also says it’s on track to cross the ₹100 crore revenue mark in FY26 and turn EBITDA positive. If it gets there, that would be a meaningful proof point that a managed water-tech subscription model can grow without burning forever.

    That’s the real story. Not just another round. A test of whether a recurring revenue, IoT-enabled, service-first consumer business can win in a category dominated by legacy appliance brands. The next 12 to 18 months will tell us if this DrinkPrime funding bump turns into durable scale or just a nicer valuation on paper.

    Read how OfficeBanao raised $7.7 million in funding from Lightspeed and why investors are backing its tech-led push to bring more structure to India’s fragmented office interiors market.

    FAQ

    How much has DrinkPrime raised in its latest round?  

    DrinkPrime raised ₹20 crore in an extended Series A round, along with an undisclosed debt component. New investors Mirabilis Investment Trust and Artha Continuum Fund joined the round. The funding pushed the Bengaluru startup’s valuation to ₹340 crore, or about $36.8 million.

    What does DrinkPrime actually sell to customers?  

    DrinkPrime offers subscription-based RO+UV water purifiers rather than one-time hardware sales. Plans start at ₹349 per month and include installation and maintenance. Its lineup includes DrinkPrime Copper, DrinkPrime Alkaline, DrinkPrime UTS, DrinkPrime RO+, and DrinkPrime Under the Sink for different household needs.

    Who founded DrinkPrime and what is known about them?

    DrinkPrime was founded in 2016 by Manas Ranjan Hota and Vijender Reddy Muthyala. Publicly available details on earlier ventures or exits are limited, but their execution record is visible in DrinkPrime’s scale: more than 2 lakh households served and expansion across major urban markets.

    Why is DrinkPrime funding significant for the market?  

    The latest DrinkPrime funding round matters because it backs a subscription-first alternative to traditional purifier ownership. The company grew FY25 revenue 54% to ₹72.1 crore, cut net loss to ₹11.5 crore, and says it aims to reach 1 million households and 20 cities in three years.